Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Non-small cell lung cancer • Ohio State University
What would you choose as the second line treatment option for a stage IV EGFR mutant lung adenocarcinoma that has progressed on osimertinib?
Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?
Answer from: Medical Oncologist at Academic Institution
The best choice for 2nd line treatment after progression on osimertinib depends on multiple factors. If a patient has progressive disease in only 1 area while all other areas are well controlled, you could consider local therapy (SBRT or EBRT) to that one area of progression, and continue the osimer...
Sign in or Register to read more